# Redmile Group: portfolio, investments and team > Redmile Group is a vc firm based in United States. 129 investments on record, 24 in the last 12 months, latest Sept 2026. Source: https://millionrounds.com/fund/redmile-group (Millionrounds; every figure on the page links to its filing or article) United States · [Investor](https://millionrounds.com/investors) # Redmile Group Last cheque observed Sep 2026; 129 cheques on record. Deploying now New fund $122M, Jul 2022 VC firm Seed Series A Series B Healthtech Mental Health Longevity Deploying now **86%** of best year **24** **cheques in 12 months**, 129 on record Since the last cheque **55** days **00** hrs **00** min **00** sec Median round **$83M** Rounds led **2 of 129** Sole investor **2 rounds** Exits **3 from the portfolio** Mostly in **United States, 93%** Pitch Redmile Group ## Redmile Group highlights - 01 24 cheques in the last 12 months - 02 Mostly Series B and Series C: 68% of its rounds - 03 Sole investor in 2 rounds, median $90M - 04 3 exits from the portfolio ## What they do > Filed 1 private fund offering with the SEC, the most recent in 2022-07 From their own website - **Type:** VC firm (from a list, unverified) - **Cheque size:** Not stated - **Stages:** Seed Series A Series B Growth Pre-IPO - **Sectors:** Healthtech Mental Health Longevity - **Based in:** San Francisco, United States - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **129 appearances** - **2026** 18 rounds - **Sept** **[One Biosciences](https://millionrounds.com/company/one-biosciences)** Grant · FR **$3.8M** With 3 others - **Aug** **[Bios Life](https://millionrounds.com/company/bios-life)** Seed · US **$25M** With 2 others - **Jul** **[Neurogene](https://millionrounds.com/company/neurogene)** US **$125M** With 4 others - **Jul** **[Annexon Biosciences](https://millionrounds.com/company/annexon-biosciences)** Debt · US **$50M** With 3 others - **Jun** **[Shattuck Labs](https://millionrounds.com/company/shattuck-labs)** US **$75M** With 4 others - **Jun** **[Absci](https://millionrounds.com/company/absci)** US **$100M** With 3 others - **Jun** **[Lycia Therapeutics](https://millionrounds.com/company/lycia-therapeutics)** Series D · US **$75M** With 3 others - **Jun** **[Aurinia Pharmaceuticals](https://millionrounds.com/company/aurinia-pharmaceuticals)** CA **$3.1M** With 2 others - **Jun** **[Neuron23](https://millionrounds.com/company/neuron23)** Grant · US **$2.5M** With 3 others - **Jun** **[ALX Oncology](https://millionrounds.com/company/alx-oncology)** Debt · US **$10M** With 4 others - **Jun** **[Nuvation Bio](https://millionrounds.com/company/nuvation-bio)** Debt · US **$250M** With 4 others - **May** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** US **$550K** With 1 other - **May** **[Cabaletta Bio](https://millionrounds.com/company/cabaletta-bio)** US **$150M** With 4 others - **Apr** **[Oruka Therapeutics](https://millionrounds.com/company/oruka-therapeutics)** US **$700M** With 3 others - **Mar** **[Ovid Therapeutics](https://millionrounds.com/company/ovid-therapeutics)** US **$60M** With 3 others - **Mar** **[Scholar Rock](https://millionrounds.com/company/scholar-rock)** Debt · US **$100M** With 3 others - **Mar** **[Ambrosia Biosciences](https://millionrounds.com/company/ambrosia-biosciences)** Series B · US **$100M** With 3 others - **Feb** **[Beam Therapeutics](https://millionrounds.com/company/beam-therapeutics)** Debt · US **$100M** With 5 others - **2025** 18 rounds - **Dec** **[Kalaris Therapeutics](https://millionrounds.com/company/kalaris-therapeutics)** US **$50M** With 3 others - **Dec** **[Kymera Therapeutics](https://millionrounds.com/company/kymera-therapeutics)** US **$602M** With 4 others - **Dec** **[Wave Life Sciences](https://millionrounds.com/company/wave-life-sciences)** US **$350M** With 4 others - **Nov** **[Invivyd](https://millionrounds.com/company/invivyd)** US **$125M** With 5 others - **Nov** **[Bambusa Therapeutics](https://millionrounds.com/company/bambusa-therapeutics)** Venture · US **Undisclosed** With 3 others - **Nov** **[Saluda Medical](https://millionrounds.com/company/saluda-medical)** Venture · US **$30M** With 3 others - **Oct** **[ADC Therapeutics](https://millionrounds.com/company/adc-therapeutics)** CH **$60M** With 3 others - **Oct** **[Rapt Therapeutics](https://millionrounds.com/company/rapt-therapeutics)** US **$250M** With 6 others - **Oct** **[Nurix Therapeutics](https://millionrounds.com/company/nurix-therapeutics)** US **$250M** With 5 others - **Sept** **[Oruka Therapeutics](https://millionrounds.com/company/oruka-therapeutics)** US **$180M** With 3 others - **Aug** **[Prime Medicine](https://millionrounds.com/company/prime-medicine)** US **$5.0M** With 4 others - **Aug** **[Strand Therapeutics](https://millionrounds.com/company/strand-therapeutics)** Series B · US **$153M** With 6 others - **Jul** **[Absci](https://millionrounds.com/company/absci)** US **$50M** With 3 others - **Jul** **[Quantum SI](https://millionrounds.com/company/quantum-si)** US **$50M** With 2 others - **May** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** US **$16M** With 1 other - **Apr** **[Attovia Therapeutics](https://millionrounds.com/company/attovia-therapeutics)** Series C · US **$90M** With 3 others - **Feb** **[Bambusa Therapeutics](https://millionrounds.com/company/bambusa-therapeutics)** Series A · US **$90M** With 3 others - **Feb** **[Abcuro](https://millionrounds.com/company/abcuro)** Series C · US **$200M** With 5 others - **2024** 7 rounds - **Nov** **[Replimune Group](https://millionrounds.com/company/replimune-group)** US **$140M** With 5 others - **Jul** **[GRO Biosciences](https://millionrounds.com/company/gro-biosciences)** Series B · US **$60M** With 4 others - **Jun** **[Entrada Therapeutics](https://millionrounds.com/company/entrada-therapeutics)** US **$100M** With 6 others - **Jun** **[CorVent Medical](https://millionrounds.com/company/corvent-medical)** Grant · US **$3.0M** With 2 others An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team Named by the firm itself, on a filing, its Form ADV or its company registration **11 named** AN **Amrit Nagpal** Executive Officer i Filing they signed BR **Bryan Ranney Crapo** Chief Operating Officer i Form ADV GV **Gerard van Hamel Platerink** Managing Director of General Partner i Filing they signed JK **Jennifer Kate Ciresi** General Counsel and Chief Compliance Officer i Form ADV JC **Jeremy Charles Green** Managing Member of the Managing Member of the General Partner i Filing they signed JD **Joshua Damian Garcia** Chief Financial Officer i Form ADV MS **Michael Stewart Lee** Managing Director i Form ADV ML **Mike Lee** Member of General Partner i Filing they signed OJ **Owen John Leary** Managing Director i Form ADV RF **Rob Faulkner** Member of General Partner i Filing they signed RC **Robert Carrington Faulkner** Managing Director i Form ADV We also hold **13** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## What the register says From the firm's own filings with the SEC, which it must file accurately by law **$4.7B** assets it manages Oct 2026 **Registered** investment adviser full reporting to the SEC - **Legal name:** Redmile Group, LLC - **SEC number:** CRD 143606 Funds on its Form ADV **18** private funds, **$7.2B** in gross assets · filed Jul 2024 Hedge **8** Venture **7** Private equity **3** - Redco II Master Fund, L.P. *Hedge* 41 investors $1.5B - Redmile Biopharma Investments III, L.P. *Private equity* 330 investors $1.2B - Redmile Capital Offshore II Master Fund, LTD. *Hedge* 8 investors $962M - Redmile Biopharma Investments II, L.P. *Venture* 138 investors $828M - Redmile Capital Offshore Master Fund, LTD. *Hedge* 217 investors $729M - Redmile Capital Fund, L.P. *Hedge* 348 investors $654M - Redmile Strategic LONG ONLY Trading SUB, LTD. *Hedge* 47 investors $286M - RAF, L.P. *Venture* 2 investors $261M - Redmile Strategic Trading SUB, LTD. *Hedge* 115 investors $212M - Redmile Growth Investments I, L.P. *Venture* 3 investors $157M And 8 more on the filing. ## Exits from the portfolio Companies it backed that were later bought or listed **3 in all** **[Scioderm](https://millionrounds.com/company/scioderm)** Bought by Amicus Therapeutics **$847M** Aug 2015 **[Foundation Medicine](https://millionrounds.com/company/foundation-medicine)** Bought by Roche **Undisclosed** Jan 2015 **[Foundation Medicine](https://millionrounds.com/company/foundation-medicine)** Listed **$108M** Jul 2013 An exit counts when it came after the firm's first round in the company. From historical deal records. New fund on file **$122M** raised in Jul 2022 From its SEC filing, not a journalist: a firm that has just raised has money to deploy. ## The cheque Seed Series A Series B Median round joined **$83M** the round, not its cheque Alone, median **$90M** Led 2 of 129 rounds **2%** - **Sole investor:** 2 rounds - **Last cheque:** Sept 2026 - **Exits:** 3 from the portfolio Rounds by stage said on their site - Series B said *25* - Series C *22* - Series A said *10* - Series D *7* - Debt *5* - Seed said *-* - Growth said *-* Cheques by month Led Joined Nov 2023 Oct 2026 Often in the room with - [Perceptive Advisors](https://millionrounds.com/fund/perceptive-advisors) 25 - [RA Capital Management](https://millionrounds.com/fund/ra-capital-management) 20 - [Cormorant Asset Management](https://millionrounds.com/fund/cormorant-asset-management) 19 - [Janus Henderson Investors](https://millionrounds.com/fund/janus-henderson-investors) 18 - [Samsara BioCapital](https://millionrounds.com/fund/samsara-biocapital) 17 - [Wellington Management](https://millionrounds.com/fund/wellington-management) 16 **Pitching Redmile Group?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as Redmile Group. A count of rooms they were both in, not a relationship either has claimed. [**Perceptive Advisors** Asset manager **25** rounds together](https://millionrounds.com/fund/perceptive-advisors)[**RA Capital Management** Private equity **20** rounds together](https://millionrounds.com/fund/ra-capital-management)[**Cormorant Asset Management** Private equity **19** rounds together](https://millionrounds.com/fund/cormorant-asset-management)[**Janus Henderson Investors** Private equity **18** rounds together](https://millionrounds.com/fund/janus-henderson-investors)[**Samsara BioCapital** VC firm **17** rounds together](https://millionrounds.com/fund/samsara-biocapital)[**Wellington Management** VC firm **16** rounds together](https://millionrounds.com/fund/wellington-management)[**Casdin Capital** VC firm **13** rounds together](https://millionrounds.com/fund/casdin-capital)[**Fidelity** VC firm **12** rounds together](https://millionrounds.com/fund/fidelity)[**Foresite Capital** Private equity **12** rounds together](https://millionrounds.com/fund/forsite-capital)[**OrbiMed** Private equity **12** rounds together](https://millionrounds.com/fund/orbimed)[**New Enterprise Associates** VC firm **11** rounds together](https://millionrounds.com/fund/new-enterprise-associates)[**Deerfield** VC firm **10** rounds together](https://millionrounds.com/fund/deerfield) ## Recently backed The latest companies Redmile Group put money into. [**One Biosciences** $3.8M · Sept 2026](https://millionrounds.com/company/one-biosciences)[**Bios Life** $25M · Aug 2026](https://millionrounds.com/company/bios-life)[**Neurogene** $125M · Jul 2026](https://millionrounds.com/company/neurogene)[**Annexon Biosciences** $50M · Jul 2026](https://millionrounds.com/company/annexon-biosciences)[**Shattuck Labs** $75M · Jun 2026](https://millionrounds.com/company/shattuck-labs)[**Absci** $100M · Jun 2026](https://millionrounds.com/company/absci) ## Quick answers about Redmile Group ### What does Redmile Group invest in? Redmile Group invests most often at Series B and Series C (68% of the rounds on record), in sectors such as Healthtech, Mental Health and Longevity. ### How active is Redmile Group? 129 investments on record, 24 of them in the last 12 months, and it led 2. The most recent was in Sept 2026. ### What has Redmile Group invested in recently? Its most recent investments on record: One Biosciences (Grant, Sept 2026), Bios Life (Seed, Aug 2026) and Neurogene (Undisclosed round, Jul 2026). ### How big are Redmile Group's cheques? The median round it joins is $83M. ### Does Redmile Group lead rounds? Sometimes: it led 2 of its 129 investments on record (2%). ### Where does Redmile Group invest? Most of the companies it backs are in the United States (93%). ### Is Redmile Group investing now? Yes: it is actively investing, with 24 investments in the last 12 months. ### Who does Redmile Group invest alongside? Most often Perceptive Advisors (25 rounds together), RA Capital Management (20 rounds together) and Cormorant Asset Management (19 rounds together). ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=redmile-group) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=redmile-group)